30 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
24 Jan 24
Results of Operations and Financial Condition
5:10pm
window before tissue injury and fibrosis occur.
A patient-centric experience. We plan to dose TOUR006 as a subcutaneous, low-volume (≤1 mL) injection once … , and/or injury. Additionally, IL-6 has demonstrated the ability to upregulate cell adhesion molecules and plays a role in vascular permeability.
Following
424B3
TRML
Tourmaline Bio Inc
15 Sep 23
Prospectus supplement
6:31am
and wastes. Talaris cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from Talaris … that Talaris may develop;
termination of clinical trial sites or entire trial programs;
injury to Talaris’ reputation and significant negative media
S-4/A
6vgkg7np y4a
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
EX-10.5
jkzye2zhxt7ld2x
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
S-4
nc591sq ui
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
8-K
EX-99.1
15d2s wo8nl
12 May 22
Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update
4:07pm
10-K
9zr2v92f
17 Mar 22
Annual report
4:31pm